Novo GLP-1 drug shows less lean mass loss than rivals, study says

A study found tirzepatide users lost 1.1% more lean body mass than semaglutide users after 3 months and 2.0% more after 12 months, despite tirzepatide producing greater average weight loss. Among patients who lost more than 20% of body weight, about 10% of tirzepatide users lost over 5% of lean mass versus fewer than 7% of semaglutide users. The report is pre-peer review and does not establish causation, but it may modestly affect perceptions of the two GLP-1 drugs.

Analysis

This is mildly negative for NVO, but the market should treat it as a differentiation issue rather than a thesis break. The key second-order effect is that as GLP-1 adoption broadens beyond pure weight-loss seekers into older, frailer, or more active patients, tolerability and body-composition messaging matter more than headline efficacy; that favors the company that can credibly claim better preservation of function, not just scale weight loss. In that framing, the study is less about one drug being "better" and more about segmentation: a meaningful slice of the market may trade some efficacy for lower perceived muscle-risk, especially if physicians begin screening for musculoskeletal comorbidity.

The near-term risk for NVO is not reimbursement loss but narrative compression. Over the next 1-3 months, even modest evidence that semaglutide is the "safer body-comp option" can slow switching into the more potent class competitor because prescribers will anchor on long-duration adherence and functional outcomes, not just pounds lost. The offset is that this data can also widen the total market by reducing fear around chronic use; if the debate shifts to exercise/nutrition co-therapy, companies selling digital coaching, protein/nutrition solutions, or DEXA/body-composition monitoring could see demand lift.

The biggest contrarian point is that the study may actually reinforce semaglutide's positioning in older, higher-risk patients, where preserving lean mass matters more than maximizing absolute weight loss. If that cohort is larger than the current market assumes, NVO's franchise could be more resilient than the headline implies, while Lilly's edge in efficacy becomes a double-edged sword for persistence in real-world use. The real catalyst to watch is physician guidance over the next 1-2 quarters; if labeling, guidelines, or payer criteria start emphasizing functional outcomes, the relative advantage could swing back toward NVO even if it continues to trail on raw weight-loss magnitude.

Key Decisions for Investors

• Trim NVO into strength over the next 1-2 sessions; the risk/reward is less attractive for a pure long until there is evidence the market is pricing this as a cohort-specific issue rather than a franchise-wide one.
• Pair trade: long NVO / short LLY for 4-8 weeks if the spread widens further on muscle-loss headlines; this is a relative-value expression on function/tolerability versus efficacy, with the stop on any broad GLP-1 reacceleration in prescription growth.
• Buy short-dated NVO puts or put spreads into any post-news bounce; downside should be time-limited but can persist for 2-6 weeks if sell-side models begin haircutting switching assumptions.
• Prefer ancillary winners over the drug makers: long healthcare-services or digital-weight-management names that can monetize exercise adherence, nutrition, and body-comp monitoring over the next 6-12 months.
• If holding NVO for the long term, use this as a catalyst to add only on weakness after guideline/physician feedback is known; the best entry is likely after the market distinguishes between cosmetic weight loss and medically supervised chronic therapy.